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Abstract
Antiretroviral agents (ART) have the potential to prevent HIV transmission by reducing the
concentration of HIV in blood and genital secretions. Indeed, mathematical models with favorable
assumptions suggest the potential of ART to stop the spread of HIV. Empirical results from
ecological and population based studies, and several short term observational studies involving
HIV discordant heterosexual couples suggest that ART reduces HIV transmission. A multinational
randomized controlled trial (NIH NPTN052) also examining the reliability and durability of ART
as prevention in HIV discordant couples is underway. The latter and other studies also consider
sexual risk taking behavior, and transmission of HIV resistant variants when ART is used as
prevention. Early HIV detection and treatment (“test and treat”) are being considered as an
important prevention strategy. In this article, we review the data supporting the use of ART to
prevent HIV transmission, and critically examine the public health implications of this strategy.
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Introduction
For every individual who receives HIV treatment it is estimated that 4 more require
treatment [1]. HIV prevention efforts have lagged behind advances in treatment, and the
development of a preventive vaccine has proven to be a truly daunting challenge. Intense
interest has developed in the usage of antiretroviral drugs to prevent transmission [2].
Indeed, the belief in the power of HIV suppression to stop secondary transmission (from an
infected index case to a sexual partner) is so strong that the Swiss AIDS Commission issued
a “declaration” indicating that under some circumstances discordant couples might engage
in unprotected intercourse with minimal risk [3]. Mathematical models argue that we can
simply treat our way out of the epidemic [4]. Early HIV detection and treatment (test and
treat strategies) are being considered as an important prevention strategy [5]. The purpose of
Corresponding Author: Myron S. Cohen, MD. J. Herbert Bate Distinguished Professor, Professor of Medicine, Microbiology and
Immunology and Public Health, 130 Mason Farm Road, Bioinformatics Building, UNC Chapel Hill, Chapel Hill, NC, 27599-7030.
Phone: 919-966-2536. Fax: 919-966-6714. mscohen@med.unc.ed.. Alternative Corresponding Author: Cynthia L. Gay, MD, MPH.
Division of Infectious Disease, University of North Carolina at Chapel Hill, 130 Mason Farm Road, CB #7030, Chapel Hill
27599-7030. Phone: 919.843.2726. Fax: 919.966-8928. Cynthia_gay@med.unc.edu..
No Conflicts of interest.
No Conflicts of interest.
Neither author has any conflicts of interest to report.
NIH Public Access
Author Manuscript
Clin Infect Dis. Author manuscript; available in PMC 2014 August 28.
Published in final edited form as:






















this article is to review the data that support the belief that ART may serve to prevent
transmission, and to critically examine the public health implications of this strategy. This
article is meant to provide a sober view of the actual potential of ART for prevention.
HIV transmission
Each HIV transmission event results from exposure to blood, a blood product or bodily
secretions contaminated with HIV-1 [6]. The probability of a transmission event whether
from blood, sex, or vertical transmission broadly correlates with the concentration of HIV-1
in the host secretion. The most widely cited transmission study entailed a retrospective
analysis of nearly 15,000 people living in the Rakai district of Uganda [7]. HIV transmission
was studied in couples retrospectively assembled through careful analysis of the data. The
probability of an HIV transmission reflected the blood viral burden of the index case with no
transmission events occurring among individuals with a blood viral burden less than 3,500
HIV RNA copies/ml. Nearly half of transmission events could be traced to infected subjects
with blood viral burden exceeding 35,000 copies/mL. These results have been confirmed in
prospective studies of discordant couples [8, 9].
However, the limitations of these results are generally overlooked. First, the number of
transmission events reported in these studies is very unlikely to be correct as HIV
transmission was not defined by matching viral sequences between the index case and
seroincident partner. When viral sequences have been analyzed in studies of transmission in
discordant couples 9-13% of transmission events prove to involve a second, unsuspected
sexual partner [10, 11]. Second, transmission events followed prospectively in studies of
discordant couples are not representative of the general epidemic because the very efficient
transmission during acute HIV infection is not observed. Indeed, it is precisely because the
Rakai, Uganda study was not a prospective discordant couples study that transmission
during acute and early HIV infection was captured [7], and demonstrated the most efficient
transmission of HIV [10]. Finally, sexual transmission must reflect HIV-1 in the genital
secretions, not the blood, and the correlation between blood and genital secretions is poor
[12] except when subjects are given ART [13].
Effects of ART on Viral Load in the blood and genital tract
There are now twenty-five antiretroviral agents available for the treatment of HIV-1
infection. Through the use of triple antiretroviral combinations, HIV-1 replication can be
effectively suppressed to <50 copies in most people over several weeks [14]. However, even
after suppression very low level viremia persists, integrated HIV can be detected in cellular
DNA [15], and the latent pool of HIV renders HIV incurable [16].
Antiretroviral therapy reduces the likelihood of HIV RNA recovery from cervical secretions.
HIV-1 RNA levels in plasma and genital secretions declined rapidly and in parallel in a
study among Kenyan female sex workers initiating non-nucleoside reverse transcriptase
inhibitor-based ART [17]. However, the suppression of HIV-1 in the genital tract is
incomplete; intermittent shedding of HIV-1 in genital secretions during apparent complete
suppression of blood viral replication is to be expected. In the prior study of 20 women, HIV
RNA was recovered in cervical and vaginal secretions through 28 days of treatment in half
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of subjects [17]. In another study of women starting ART, the detection of HIV RNA in
genital secretions decreased from 51% before ART to 15% following treatment initiation
[18]. In general, suppression of HIV in blood does not assure that HIV will not be recovered
from female genital secretions among women with undetectable plasma viral load [19, 20].
In addition, the concentration of HIV in female genital secretions recovered is greatly
affected by the collection method used, [21-23], and by menses [24].
HIV shedding in semen has also been extensively studied [21, 25, 26]. The concentration of
HIV in semen is generally lower than in plasma [21, 25], but can equal or exceed blood in
the setting of inflammation as seen with sexually transmitted diseases (STDs) [26].
Suppression of HIV in blood does not assure that replicative HIV will not be recovered in
semen [27-30]. Most recently, Sheth et al. studied HIV shedding in 25 men with durable
suppression of HIV-1 in blood [31]. HIV RNA was detected in semen in 12 of 25 (48%)
participants, and in 4 of 25 (16%) with more than 5000 copies/mL recovered in semen. HIV
was detected in semen at 19 of 116 clinic visits when blood viral load was less than 50
copies/ml.
The choice of antiviral agents makes a difference. While most antiretrovirals can penetrate
the genital tract, protease inhibitors achieve limited concentration in genital secretions [30,
32-35], and distinct resistant HIV-1 variants in blood and seminal plasma from individuals
on therapy with protease inhibitors supports their limited penetration into the genital tract
[32, 34].
In addition, STDs can increase shedding of HIV-1 during ART therapy [36]. Sadiq et al.
demonstrated that treatment of STDs decreased seminal plasma HIV levels, more than 20-
fold in the case of gonococcal urethritis [37]. Nagot et al. reported better suppression of
HIV-1 in the female genital tract only when twice daily valacyclovir was added to an ART
[38], but herpes simplex virus (HSV) suppression does not prevent HIV transmission (see
below). These results emphasize the compartmentalization of HIV-1 reflected in discordant
viral RNA levels [39, 40], different viral phenotypes and genotypes recovered from blood
and the genital tract [39, 41, 42] and local replication of HIV in the genital tract [43].
HIV RNA has also been evaluated in rectal specimens during treatment [44], and these
results are extremely important for HIV prevention among men who have sex with men
(MSM), as well as many heterosexual couples. Among 233 MSM in Seattle, HIV RNA
could be detected in anorectal mucosal swab specimens in 49% of the men who were not
receiving therapy, 30% of men receiving therapy that did not include a protease inhibitor,
and 17% of men on triple drug therapy that included a protease inhibitor [44]. HIV DNA
was recovered from 58% of specimens harvested from men not receiving therapy and 43%
of men taking triple drug therapy including a protease inhibitor.
ART and Suppression of HIV Transmission
It seems clear that current ART suppresses but does eliminate shedding of HIV in genital
secretions. Accordingly, the magnitude of HIV transmission during therapy is impossible to
estimate. Three lines of evidence have been used to determine the prevention benefits of
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ART: retrospective and prospective observational studies of couples, ecologic community
studies and an ongoing randomized trial.
Observational results
Musicco and coworkers conducted a retrospective study of HIV transmission among 436
HIV discordant couples [45]. Among the fifteen percent of men with more advanced disease
who took zidovudine, a decrease in the relative risk of HIV transmission to a female sexual
partner (O.R =0.5, 95% CI 0.1-0.9) was noted. Castilla et al. retrospectively compared HIV
transmission in 386 serodiscordant couples in the pre-HAART, early HAART and post-
HAART periods (1991-2002), and reported an 80% reduction in HIV transmission
following the implementation of HAART [46].
More recently, results from HIV discordant couples in Uganda, Zambia and Rwanda have
been reported. [47, 48]. Working in Uganda, Were and colleagues conducted a household
survey and found an HIV prevalence of 37.1% among adults aged 25 to 44; 43% of spouses
of patients eligible for ART were HIV negative [47], emphasizing the frequency of
discordant couples and the potential to prevent transmission. The apparent low rate of
transmission reported reflects the complexity of HIV transmission within couples, but does
not assure that future HIV transmission will not occur [49]. Using a model which
incorporated partner HIV status and viral load in the index partner, these same investigators
estimated that the risk of HIV transmission decreased from 45.7 to 1.0 transmission per
1000 person-years in 454 of 926 participants over 24 months when the infected partner was
provided ART [50]. Sullivan et al. (2009) followed 2993 discordant couples in Zambia and
Rwanda for a median of 512 days [48]. Subjects who required ART for falling CD4 counts
were less likely to transmit HIV to their sexual partners than those who remained untreated
(hazard ratio [HR] = 0.21, CI 0.09 to 0.52). It should be noted that 4 transmission events
occurred in participants on therapy which has major implications for counseling (see below)
since the provision of ART does not eliminate the risk of transmitting to a partner. This
finding raises real concern regarding the Swiss Declaration which assumed extremely low
HIV transmission risk [3].
The effects of ART on HIV transmission have also been assessed by statistically analyzing
population-level trends. In San Francisco, Porco et al. noted a 48% decline in predicted
incidence of HIV in a large closed MSM cohort ascribed to availability of ART [51]. In
Taiwan, a 48% reduction in expected HIV cases was noted after the introduction of free
ART in 1997, where country-wide surveillance has occurred since 1989 [52]. In a study of
1062 MSM (the Amsterdam Cohort Study), Couthino et al. reported that the introduction of
ART in Amsterdam in 1996 was associated with increased risky sexual behaviors [53] and
STDs [54]. However, a large decrease in HIV incidence was observed between 1985 and
1993, and HIV incidence has fluctuated at low levels since that time [53]. In contrast, Katz
et al. reported that widespread use of ART had not reduced incident HIV infections in San
Francisco [55].
While population/epidemiologic studies are interesting, they are greatly limited by the data
collected and several kinds of bias. In none of the studies described above could the exact
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risk of HIV exposure be characterized, so it is impossible to prove that people receiving
ART actually encountered the subjects included in surveillance.
HPTN052: A Randomized Controlled Trial
HPTN052 is a study supported by NIH through the prevention trials network. The study is
designed to examine several linked questions. First, can ART prevent sexual transmission to
a discordant partner over 5 years? The duration of benefit is extremely important. To
examine this question, infected index subjects are randomized to immediate versus delayed
ART based on clinical history and CD4 counts. To measure a 30% reduction in HIV
transmission ascribed to ART 1750 couples must be followed. Because participants must be
treated at high CD4 counts (350-550) and ART started before CD4 counts fall to low levels
(<250), this study can also determine whether earlier ART will offer clinical benefit. Recent
observational studies from developed countries suggest that earlier therapy reduces HIV-
related morbidity [56] and mortality [57]. However, it is not known whether the benefits of
earlier therapy (CD4 >350 cells/mm3) extend to subjects living in developing countries
because cardiovascular disease was so commonly observed in those for whom therapy was
delayed in the US/European study [56]. It is entirely clear that CD4 count should not be
allowed to fall below 200 cells/ mm3 [58]. To date, HPTN052 is following more than 1500
couples and enrollment will be complete in 2010. The majority of index cases have HIV
viral load > 5000 copies/ml blood and 30% have >50,000 copies/ml blood at enrollment
emphasizing the risk for HIV transmission (reviewed at www.hptn.org).
Other Considerations: Newer thinking about the HIV infected subject
Stage of HIV Infection
Patients with acute HIV infection represent a very high risk for transmission [10]. However,
the detection of acute HIV requires specific testing for HIV RNA or p24 antigen, not
available in many resource poor settings as well as a high clinical suspicion given protean
symptoms [59]. There are no data to support emergent treatment of patients with AHI [60],
although it appears that earlier treatment of HIV may reduce the pool of latently infected
cells [16].
ART Impact on Sexual Behavior
The impact of ART on sexual behavior among HIV-infected individuals remains critical but
studies to date have produced variable results [61]. A meta-analysis of the effect of ART on
sexual behavior in developed countries did not find an increase in high risk sexual behavior
between treated and untreated HIV-infected persons [62]. However, unprotected sex was
reported more often by HIV-infected individuals who perceived that therapy prevented
transmission or who expressed less HIV threat given the availability of ART.
Other studies have suggested that advances in HIV treatment have resulted in sexual
disinhibition [63-66]. Among intravenous drug users on ART, a 3-fold increase in
unprotected sex following ART initiation was observed [66]. Studies among HIV-infected
MSM have found that HIV-infected MSM less concerned about transmitting HIV to sexual
partners due to ART availability were more likely to engage in unprotected anal intercourse
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[63, 67]. In Canada, risk behavior was associated with the perception that ART reduced HIV
transmission risk and that increased unsafe sex was related to advances in HIV treatment;
however, other factors such as safer sex fatigue, use of poppers and serosorting were more
strongly correlated with unsafe risk behavior [68]. In an Australian cohort, frequent
unprotected anal intercourse with casual partners was reported more often by HIV- infected
MSM on ART; although 70.7% of unprotected anal intercourse with casual partners was
reported by a minority (10%) of participants [69]. In contrast, another study of MSM found
no increase in risk behavior for those on ART [70].
In a study of HIV positive men and women, only HIV treatment beliefs were associated with
unprotected intercourse with serodiscordant partners [61]. Among a study focused on HIV
positive women, study participants who felt that ART was associated with reduced HIV
transmission were more likely to report less consistent condom use [71] .
Studies have also produced discrepant data on the association between HIV viral load
suppression and risky sexual behavior. Some studies have suggested that undetectable viral
loads were associated with increased sexual risk behaviors [53, 62, 72, 73]. However, one
study among HIV-infected MSM found that even with detectable viremia unprotected anal
intercourse transpired [74]Other studies found no association between viral load and
increased sexual risk behavior [75, 76].
Kennedy and colleagues conducted a systematic review on the impact of ART on sexual
behavior in people living in developing countries [77]. Only three studies [50, 78, 79]
conducted in Africa met criteria for inclusion, and each found that approximately half of
HIV-infected participants reported sexual abstinence. The review concluded that access to
ART was not associated with high risk sexual behavior, but in some cases, with reduced
sexual risk behavior. Subsequent studies in Uganda, Kenya and Brazil have found that
participants on ART were more likely to report protected sex compared with untreated
participants [80-82]. One study in Cape Town, South Africa found no difference in reported
unprotected sex at last encounter between 520 participants who recently initiated ART and
404 participants waiting to start ART [83]. However, a recent study in Cǒte d'Ivoire reported
that unprotected sex among participants starting ART increased from 20.4% to 30.1%
(p<0.0001) at 6 months compared with stable risk behavior among untreated participants
[84]. It bears noting that only a few studies [50, 66, 78, 84] on the affects of ART on sexual
behavior were prospective cohort studies which adjusted for baseline sexual behavior before
the initiation of ART, and results from these studies were conflicting as above. In addition,
very little research has been done on MSM in resource constrained countries, limiting the
ability to apply findings from studies of MSM living in developed countries to such
populations.
The Public Health Implications of ART: Modeling
An extensive group of models have been developed (Table 1). Inevitably, the models are
bounded by assumptions about the number of people to be treated, the degree and durability
of suppression, and adherence to therapy. The more optimistic the assumptions applied to
the models, the greater the benefits of ART for a community (Table 1). Several
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mathematical modeling studies have suggested that widespread use of ART could
substantially reduce HIV incidence [85, 86], but that any possible preventative benefit of
ART could be undermined by behavioral disinhibition [85, 87-89]. Baggaley and colleagues
concluded that ART is unlikely to reduce HIV transmission due to the limited ability of
ART to prevent HIV transmission, widespread emergence of ART resistance and significant
increases in HIV risk-taking behavior [87]. However, in a recent more “utopian” model
Granich et al. argued that the HIV epidemic in Africa could be ended with universal annual
HIV testing and immediate treatment [4]. In a model constructed by Lima and colleagues,
increasing ART coverage beyond the current 50% of those with a CD4 count less than 200
cells/mm3 to 75%, 90% and 100% in the setting of stable adherence would decrease HIV
incidence by 37%, 54% and 62%, respectively, as well as per capita lifetime treatment costs
[90]. Obviously, empiric data is absolutely required to demonstrate a public health benefit
from ART. To date, no community randomized clinical trials of ART for public health
benefit have started, although such studies are necessary to determine the validity and cost-
effectiveness of such an approach [5]. The broadest coverage would result from initiation of
ART regardless of CD4, and this approach is currently being described as “Test and Treat.”
A very detailed discussion on this topic can be reviewed at the World Health Organization
(WHO) website at http://www.who.int/hiv/events/artprevention/en/index.html.[91]
Transmitted antiviral resistance
The success of ART for prevention will undoubtedly be limited by the development of
resistance. Recent studies demonstrate considerable HIV resistance in newly diagnosed
patients [92, 93]. However the rates of resistant HIV may actually be lower than expected
suggesting reduced viral fitness or other antiviral effects. In addition, resistant HIV isolates
have been detected in genital secretions [32, 34] and sexual transmission of such resistant
variants has been demonstrated [94-96].
HSV-2 suppression and HIV transmission
Among the STDs, HSV-2 has been considered particularly important because of widespread
world-wide infection and documented effects on HIV genital tract shedding [97]. More than
one meta-analysis has ascribed significant HIV transmission to HSV as a co-factor [98-100].
However, recent clinical trials designed to suppress HSV-2 in HIV negative subjects at risk
[101], and HSV in HIV-infected subjects [102] failed to reduce transmission of HIV-1. Such
findings were unexpected and it seems likely that acyclovir used in these trials was not
sufficiently suppressive to override other factors. In addition, acyclovir has a weak direct
effect on HIV that might help account for partial reduction in blood viral load [103].
Conclusion
Literally days after zidovudine (AZT) was described in the late 1980s, the public health
implications of ART were considered. A series of studies demonstrated the ability of
antiviral agents to concentrate in genital secretions [104], and to reduce recovery of HIV
[28, 105, 106]. These results provided the biological plausibility for the belief that HIV
treatment can serve as prevention. Enthusiasm for this approach has recently been driven by:
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i) the failure of other behavioral and biological prevention efforts to end the epidemic [107];
ii) cheaper, safer and simpler ART regimens; iii) the widespread availability of ART in
developing countries; iv) the optimism of mathematical modelers (see above) and some
policy makers [108]. Accordingly, the public health benefits of ART have now taken center
stage, not just for treatment of the infected subject, but as pre-and post exposure prophylaxis
well [2, 109]. While this momentum is exciting, threats must also be weighed. Use of ART
for prevention will require much wider usage of drugs in much healthier people. Clinical and
community randomized trials are absolutely necessary to determine the actual feasibility and
benefit of this approach.
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